Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Acquired drug resistance during inadequate therapy in a young child with tuberculosis.

Garcia-Prats AJ, Willemse M, Seifart HI, Jordaan AM, Werely CJ, Donald PR, Schaaf HS.

Pediatr Infect Dis J. 2014 Aug;33(8):883-5. doi: 10.1097/INF.0000000000000336.

PMID:
25222312
2.

Pharmacokinetics of isoniazid in low-birth-weight and premature infants.

Bekker A, Schaaf HS, Seifart HI, Draper HR, Werely CJ, Cotton MF, Hesseling AC.

Antimicrob Agents Chemother. 2014;58(4):2229-34. doi: 10.1128/AAC.01532-13. Epub 2014 Feb 3.

3.

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.

Zvada SP, Denti P, Donald PR, Schaaf HS, Thee S, Seddon JA, Seifart HI, Smith PJ, McIlleron HM, Simonsson US.

J Antimicrob Chemother. 2014 May;69(5):1339-49. doi: 10.1093/jac/dkt524. Epub 2014 Jan 31.

4.

The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care.

Koegelenberg CF, Nortje A, Lalla U, Enslin A, Irusen EM, Rosenkranz B, Seifart HI, Bolliger CT.

S Afr Med J. 2013 Apr 5;103(6):394-8. doi: 10.7196/samj.6344.

PMID:
23725959
5.

Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation.

Liwa AC, Schaaf HS, Rosenkranz B, Seifart HI, Diacon AH, Donald PR.

J Trop Pediatr. 2013 Apr;59(2):90-4. doi: 10.1093/tropej/fms053. Epub 2012 Nov 21.

PMID:
23174991
6.

Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.

Kiser JJ, Zhu R, D ľArgenio DZ, Cotton MF, Bobat R, McSherry GD, Madhi SA, Carey VJ, Seifart HI, Werely CJ, Fletcher CV.

Ther Drug Monit. 2012 Aug;34(4):446-51. doi: 10.1097/FTD.0b013e31825c4bc3.

7.

Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.

8.

Pharmacokinetics of ethionamide in children.

Thee S, Seifart HI, Rosenkranz B, Hesseling AC, Magdorf K, Donald PR, Schaaf HS.

Antimicrob Agents Chemother. 2011 Oct;55(10):4594-600. doi: 10.1128/AAC.00379-11. Epub 2011 Jul 25.

9.

The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.

Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D'Argenio DZ, Fletcher CV.

J Clin Pharmacol. 2012 Apr;52(4):511-9. doi: 10.1177/0091270011402826. Epub 2011 May 10.

10.

In vitro transcorneal diffusion of the antimicrobial macrolides azithromycin and clarithromycin and the impact on microbial keratitis.

van Eyk AD, Seifart HI, Meyer D, van der Bijl P.

Cornea. 2009 May;28(4):441-6. doi: 10.1097/ICO.0b013e31818c901f.

PMID:
19411964
11.

Comparative diffusion of drugs through bronchial tissue.

van Zyl JM, Derendinger B, Seifart HI, Van der Bijl P.

Int J Pharm. 2008 Jun 5;357(1-2):32-6. doi: 10.1016/j.ijpharm.2008.01.028. Epub 2008 Jan 20.

PMID:
18295419
12.

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, Sirgel FA, Venter A, Maritz JS.

Eur J Clin Pharmacol. 2007 Jul;63(7):633-9. Epub 2007 May 16.

PMID:
17505821
13.

Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, Maritz JS, Donald PR.

Arch Dis Child. 2005 Jun;90(6):614-8.

14.

Diffusion of metronidazole released from aqueous solution and a gel through human and rabbit corneas.

van der Bijl P, van Eyk AD, Seifart HI, Meyer D.

J Ocul Pharmacol Ther. 2004 Oct;20(5):421-9.

PMID:
15650517
15.

The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.

Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, Werely C, van Helden PD, Maritz JS.

Clin Infect Dis. 2004 Nov 15;39(10):1425-30. Epub 2004 Oct 25.

PMID:
15546075
16.

Early bactericidal activity of antituberculosis agents.

Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, Maritz JS, Fourie PB.

Expert Rev Anti Infect Ther. 2003 Jun;1(1):141-55. Review.

PMID:
15482107
17.

In vitro transcorneal penetration of metronidazole and its potential use as adjunct therapy in Acanthamoeba keratitis.

van der Bijl P, van Eyk AD, Seifart HI, Meyer D.

Cornea. 2004 May;23(4):386-9.

PMID:
15097135
18.

NAT2 slow acetylator function as a risk indicator for age-related cataract formation.

Meyer D, Parkin DP, Seifart HI, Maritz JS, Engelbrecht AH, Werely CJ, van Helden PD.

Pharmacogenetics. 2003 May;13(5):285-9.

PMID:
12724621
19.

Permeability of intestinal mucosa to crystalline and tabletted isoniazid (INH).

van der Bijl P, Seifart HI, van Eyk AD.

S Afr Med J. 2003 Feb;93(2):127-8. No abstract available.

PMID:
12640883
20.

Population screening for isoniazid acetylator phenotype.

Seifart HI, Parkin DP, Botha FJ, Donald PR, Van Der Walt BJ.

Pharmacoepidemiol Drug Saf. 2001 Mar-Apr;10(2):127-34.

PMID:
11499851
21.

Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis.

Donald PR, Sirgel FA, Kanyok TP, Danziger LH, Venter A, Botha FJ, Parkin DP, Seifart HI, Van De Wal BW, Maritz JS, Mitchison DA.

Antimicrob Agents Chemother. 2000 Dec;44(12):3285-7.

22.

Second episode of tuberculosis in an HIV-infected child: relapse or reinfection?

Schaaf HS, Gie RP, van Rie A, Seifart HI, van Helden PD, Cotton MF.

J Infect. 2000 Jul;41(1):100-3.

PMID:
11041705
23.

Practical management of therapeutic diphenylhydantoin concentrations in children.

Smit A, Schoeman JF, Seifart HI, Parkin DP.

S Afr Med J. 1999 Oct;89(10):1092-7.

PMID:
10582067
24.

Massive posterior fossa tuberculous abscess developing in a young child treated for miliary tuberculosis. Possible role of very rapid acetylation of isoniazid.

Schoeman JF, Morkel A, Seifart HI, Parkin DP, Van Helden PD, Hewlett RH, Donald PR.

Pediatr Neurosurg. 1998 Aug;29(2):64-8.

PMID:
9792958
25.

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.

Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ML, Van de Wal BW, Maritz JS, Mitchison DA.

Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):895-900.

PMID:
9310010
26.

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.

Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR, van Jaarsveld PP.

Am J Respir Crit Care Med. 1997 May;155(5):1717-22.

PMID:
9154882
27.

Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient.

Botha FJ, van der Bijl P, Seifart HI, Parkin DP.

Intensive Care Med. 1996 May;22(5):443-6.

PMID:
8796397
28.

High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids.

Seifart HI, Gent WL, Parkin DP, van Jaarsveld PP, Donald PR.

J Chromatogr B Biomed Appl. 1995 Dec 15;674(2):269-75.

PMID:
8788156
29.

Isoniazid elimination kinetics in children with protein-energy malnutrition treated for tuberculous meningitis with a four-component antimicrobial regimen.

Seifart HI, Donald PR, de Villiers JN, Parkin DP, Jaarsveld PP.

Ann Trop Paediatr. 1995 Sep;15(3):249-54.

PMID:
8534045
30.

Hydrazine production in children receiving isoniazid for the treatment of tuberculous meningitis.

Donald PR, Seifart HI, Parkin DP, van Jaarsveld PP.

Ann Pharmacother. 1994 Dec;28(12):1340-3.

PMID:
7696721
31.

Therapeutic monitoring of antituberculosis drugs by direct in-line extraction on a high-performance liquid chromatography system.

Seifart HI, Kruger PB, Parkin DP, van Jaarsveld PP, Donald PR.

J Chromatogr. 1993 Sep 22;619(2):285-90.

PMID:
8263100
32.

Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status.

Donald PR, Gent WL, Seifart HI, Lamprecht JH, Parkin DP.

Pediatrics. 1992 Feb;89(2):247-50.

PMID:
1734391
33.

Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients.

Gent WL, Seifart HI, Parkin DP, Donald PR, Lamprecht JH.

Eur J Clin Pharmacol. 1992;43(2):131-6.

PMID:
1425868
34.

Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children.

Seifart HI, Parkin DP, Donald PR.

Pediatr Infect Dis J. 1991 Nov;10(11):827-31.

PMID:
1749695
35.

Serum gentamicin assay: an assessment of two different Syva EMIT and Abbot TDx instruments.

Seifart HI, van der Bijl P, Brits DA, Kotze TJ.

J Antimicrob Chemother. 1990 Apr;25(4):665-72.

PMID:
2190973
36.
37.

In vitro evaluation of ampicillin-gentamicin interactions.

Van der Bijl P, Seifart HI.

J Oral Maxillofac Surg. 1989 May;47(5):489-94.

PMID:
2709220
38.

Oligomeric substances in ampicillin preparations. A comparison of Penbritin, Famicillin and Petercillin.

van der Bijl P, Seifart HI, Parkin DP, Mattheyse FJ.

S Afr Med J. 1988 Apr 16;73(8):453-5.

PMID:
3358227
39.

Endogenous immunoreactive digitalis-like substance in neonatal serum and placental extracts.

Beyers AD, Spruyt LL, Seifart HI, Kriegler A, Parkin DP, Van Jaarsveld PP.

S Afr Med J. 1984 Jun 2;65(22):878-82.

PMID:
6729626
40.

Endogenous digoxin-like material.

Beyers AD, Spruyt LL, Seifart HI, Kriegler A, Parkin DP, van Jaarsveld PP.

S Afr Med J. 1983 Jul 9;64(2):42. No abstract available.

PMID:
6867873
41.

Anoxic energy production and contractile activity in mammalian cardiac muscle.

Siess M, Seifart HI.

Adv Myocardiol. 1980;2:295-310.

PMID:
7423046

Supplemental Content

Loading ...
Support Center